(Q45157613)

10 December 2017

title

Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine (English)

1 reference

10 December 2017

Natalie K Connors

4

0 references

Anton Middelberg

8

object named as

Anton P J Middelberg

1 reference

10 December 2017

Yap P Chuan

1

1 reference

10 December 2017

Tania Rivera-Hernandez

2

1 reference

10 December 2017

Nani Wibowo

3

1 reference

10 December 2017

Yang Wu

5

1 reference

10 December 2017

Fiona K Hughes

6

1 reference

10 December 2017

Linda H L Lua

7

1 reference

10 December 2017

publication date

22 April 2013

1 reference

Biotechnology and Bioengineering

10 December 2017

published in

1 reference

10 December 2017

volume

110

1 reference

10 December 2017

issue

9

1 reference

10 December 2017

page(s)

2343-2351

1 reference

Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians.

10 December 2017

cites work

1 reference

Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection

21 January 2018

1 reference

Quantitative analysis of virus-like particle size and distribution by field-flow fractionation.

21 January 2018

1 reference

High-level expression of soluble viral structural protein in Escherichia coli.

21 January 2018

1 reference

Virus assembly occurs following a pH- or Ca2+-triggered switch in the thermodynamic attraction between structural protein capsomeres.

21 January 2018

1 reference

Universal influenza A vaccine: optimization of M2-based constructs.

21 January 2018

1 reference

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

21 January 2018

1 reference

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

21 January 2018

1 reference

Virus-like particles as vaccines and vessels for the delivery of small molecules

21 January 2018

1 reference

Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice

21 January 2018

1 reference

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

21 January 2018

1 reference

Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies

21 January 2018

1 reference

Seroepidemiology of human polyomaviruses

21 January 2018

1 reference

Tandem repeats of T helper epitopes enhance immunogenicity of fusion proteins by promoting processing and presentation.

21 January 2018

1 reference

Microbial production of virus-like particle vaccine protein at gram-per-litre levels.

21 January 2018

1 reference

Quaternary size distribution of soluble aggregates of glutathione-S-transferase-purified viral protein as determined by asymmetrical flow field flow fractionation and dynamic light scattering.

21 January 2018

1 reference

Affinity purification of viral protein having heterogeneous quaternary structure: modeling the impact of soluble aggregates on chromatographic performance.

21 January 2018

1 reference

A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.

21 January 2018

1 reference

Virus-like particles as immunogens

21 January 2018

1 reference

Towards the preparative and large-scale precision manufacture of virus-like particles

21 January 2018

1 reference

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

Virus-like particles in vaccine development.

21 January 2018

1 reference

SWISS-MODEL: An automated protein homology-modeling server

21 January 2018

1 reference

An immunodominant, cross-reactive B-cell epitope region is located at the C-terminal part of the hamster polyomavirus major capsid protein VP1.

21 January 2018

1 reference

High-resolution structure of a polyomavirus VP1-oligosaccharide complex: implications for assembly and receptor binding

21 January 2018

1 reference

Versatile virus-like particle carrier for epitope based vaccines

21 January 2018

1 reference

A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/BIT.24907

1 reference

10 December 2017

1 reference